Top PDF Addition of incretin therapy to metformin in type 2 diabetes.
Addition of incretin therapy to metformin in type 2 diabetes.
... end of follow-up (intention to treat, last observation carried forward) versus ...34% of patients on metformin alone. ‡ 27% of patients on metformin ...38% of patients on ...
3
Treatment of type 2 diabetes.
... 4. Therapy risk and benefits As the prevalence of type 2 diabetes and the risk of severe side-effects of oral antidiabetic agents are markedly increased with aging, ...
13
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
... second-line therapy behind first-line metformin, as third-line therapy after failure of dual oral therapy or even as add-on to insulin for a majority of patients with ...
32
Rimonabant improves cardiometabolic risk factors in overweight/obese patients with poorly controlled type 2 diabetes (HbA(1c)>= 8%) on monotherapy with metformin or sulfonylureas
... circumference in a randomised clinical trial in overweight/obese patients with type 2 diabetes treated with metformin (65%) or sulfonylureas (35%) (RIO-Diabetes ...7.3% ...
3
Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.
... that incretin-based therapies are rather new approaches in the management of T2DM [15] , their PK characteristics in patients with different degrees of HI have been more extensively ...
32
Survival in people with type 2 diabetes as a function of HbA(1c).
... practitioners in the UK. The main result in this study of 48 000 patients with type 2 diabetes (cohort 1 changed from monotherapy to combination oral therapy with ...
4
DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
... burden in patients with T2D, potentially improving adherence to, and optimizing the benefits of therapy [15, ...effects of the two compounds were far from being additive and the final ...
37
Canagliflozin: A Review in Type 2 Diabetes.
... Administration In the EU, canagliflozin is approved for use as monotherapy (as an adjunct to diet and exercise, when metformin is considered inappropriate) and as an add-on therapy (to ...
20
Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.
... management of type 2 diabetes. After metformin therapy, and according to the recently updated joint American Diabetes Association (ADA)- European Association for ...
5
Systematic review: Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment
... Context Metformin is considered as the best initial pharmacological option to lower glucose concentrations in patients with type 2 diabetes mellitus ...As metformin may be ...
3
Personalising metformin therapy: a clinician's perspective
... effect of metformin on blood glucose. In a large cohort of patients with type 2 diabetes, an 80-fold variability in trough steady-state metformin plasma ...
5
Cannabinoid-1 receptor antagonists in type-2 diabetes.
... shown to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance index and C-reactive protein levels, and to increase high-density lipoprotein (HDL) cholesterol and ...
13
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
... Changes in plasma glucose, insulin, and glucagon in relation to glycaemic response after a liquid meal tolerance test were analyzed during treatment with dual add-on of dapagliflozin plus ...
44
Perceptions of insulin therapy in people with type 2 diabetes and physicians: a cross-sectional survey conducted in france
... analysis of similar questions answered by both patients and ...participation of persons with T2D in the survey ...acceptance of the survey was high (100%). In addition, the ...
11
DPP-4 inhibitors in the treatment of type 2 diabetes.
... add-on therapy and has shown clinically meaningful improvement of glycaemic control in type 2 ...leading to a median >82% DPP-4 inhibition, during 24 weeks in ...
27
Therapy: Metformin takes a new route to clinical efficacy.
... prevalence of type 2 diabetes mellitus (T2DM) has reached epidemic proportions worldwide and represents an important threat to global public health ...basis of available clinical ...
6
Type 2 diabetes mellitus and osteoarthritis
... prescribed metformin treatment at baseline and OA outcome during follow up (adjusted HR = ...However, in a case-control study performed in Taiwan, patients who have OA and T2DM receiving combination ...
12
Which incretin-based therapy for type 2 diabetes?
... dose of 1.5 mg once weekly was non-inferior to once-daily ...difference in efficacy derives from differences in dose estimations with the various once-weekly GLP-1 RAs, although ...
7
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
... production in individuals with T2DM through a 25–40% decrease in the hepatic gluconeogenesis rate as determined by 13 C nuclear magnetic resonance (NMR) spectroscopy or tracer infusion 13,14 ...Moreover, ...
51
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
... mechanisms of action that offer improved efficacy and/or better tolerability profiles and can be used either as monotherapy or in combination treatment regimens (including ...class of oral ...
12